Lexicon Pharmaceuticals, Inc.
LXRX US
LXRX USLexicon Pharmaceuticals, Inc.
United States Composite1.54
USD
-0.06
(-3.75%)
United States CompositeClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Analysts Conflicted on These Healthcare Names: Xoma (XOMA) and Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.